GH Research (NASDAQ:GHRS) Stock Price Up 3.8% – Here’s Why

GH Research PLC (NASDAQ:GHRS)’s share price shot up 3.8% during trading on Wednesday . The company traded as high as $9.60 and last traded at $9.50. 9,127 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 79,000 shares. The stock had previously closed at $9.15.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th.

GH Research Trading Up 1.4 %

The business has a fifty day simple moving average of $7.72 and a 200 day simple moving average of $10.40.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. Equities research analysts expect that GH Research PLC will post -0.85 EPS for the current fiscal year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its stake in GH Research PLC (NASDAQ:GHRS) by 11.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the period. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).